NEW YORK - Rumor and innuendo notwithstanding, the intellectual property securitization sector has been quiet for the past year. However, market participants are talking up a comparatively vigorous pipeline, including a pharmaceutical royalty-backed deal in the works.

"We are hoping to see another drug royalty closing by the end of this summer," said Peter Walsh, managing director and co-head of origination and structuring at Harris Nesbitt, speaking at Strategic Research Institute's Intellectual Property Financing and Securitization conference last week in New York.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.